Melissa Genevieve Lechner

Title(s)Assistant Professor-in-Residence, Medicine
SchoolMedicine
Emailmlechner@mednet.ucla.edu
ORCID ORCID Icon0000-0002-4744-6566 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    American Association of Immunologists, Washington, D.C.2023Oral Abstract Award
    Aramont Charitable Foundation, UCLA2021  - 2024Early-Stage Immunologist Award
    American Thyroid Association, Montreal, Canada2022Oral Abstract Award
    2021Rising Stars oral research presentation winner and abstract achievement award, Endocrine Society
    2014US Patent 8883497 B2, co-inventor, Human myeloid derived suppressor cell cancer markers
    2011“Top 10 innovations of 2011” CNN, Manhattan, NY, for research innovation
    2013Alpha Omega Alpha (AOA) Recognition Honor Medical Society

    Collapse Overview 
    Collapse Overview
    Melissa G. Lechner, MD, PhD is an Assistant Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at the UCLA David Geffen School of Medicine. Her clinical and research interests are related to endocrine disease resulting from cancer immunotherapy (onco-endocrinology) and advanced thyroid cancer. She established the Onco-Endocrinology clinic at UCLA to care for patients with endocrine side effects from cancer immunotherapy and targeted therapies. She also has expertise in thyroid nodules (including biopsy).

    Dr. Lechner leads multiple prospective clinical trials at UCLA studying thyroid disease and cancer immunotherapy. She has received funding from the American Thyroid Association, Endocrine Fellows Foundation, and National Institutes of Health for her research and has been invited to speak nationally and internationally on the role of the immune system in cancer. She has published articles in Thyroid, The Journal of Clinical Endocrinology and Metabolism, The Journal of Immunology, Cancer, and Clinical Cancer Research, including original research and invited reviews, and serves on the National Comprehensive Cancer Network of Management of Immunotherapy Toxicity Side Effects guidance panel.

    After finishing her combined MD and PhD training in the joint USC Keck School of Medicine/Cal Tech physician-scientist training program, Dr. Lechner completed residencies in internal medicine and pediatrics at Brigham and Women's Hospital and Boston Children's Hospital of the Harvard Medical School. In 2018, she joined UCLA as a clinical fellow in endocrinology and post-doctoral researcher in the prestigious Specialty Training and Advanced Research (STAR) program. In 2020, Dr. Lechner joined the faculty at UCLA.

    Current Clinical Trials
    IRB#21-000633 Mechanisms of Immune Checkpoint Inhibitor cancer therapy-associated and Spontaneous Thyroid Autoimmune Disease

    PI: Dr. Lechner (Sponsors: UCLA, USC, NIH and Aramont Charitable Foundation)

    [Archival: IRB#19-001708 Comparison of Immune Profiles in Different Thyroid Disease States (Sponsors: UCLA and NIH)]

    Purpose: Immune related adverse events are autoimmune toxicities that occur in many patients treated with immune checkpoint inhibitor (ICI) cancer therapies, and the thyroid is one of the most common organs affected. In addition, thyroid autoimmune disease affects millions of individuals worldwide and leads to the need for lifelong thyroid hormone replacement.

    Our studies seek to determine the cause of these thyroid autoimmune diseases so that disease modifying therapies can be developed.

    Involvement: The study involves collection of peripheral blood and a thyroid fine needle aspirate. Compensation is provided.

    Eligibility: Adults with active thyroid disease, including immune checkpoint inhibitor thyroid disease, autoimmune thyroid disease (such as Hashimoto’s or thyroiditis). Controls without thyroid autoimmune disease are also needed, and can include individuals with benign thyroid nodules.

    Sites: UCLA and USC



    IRB#20-000494 Immune Profiles Associated with Development of Immune Toxicities in Checkpoint Immunotherapy-Treated Cancer Patients

    PI: Dr. Lechner (Sponsors: UCLA and NIH)

    Purpose: Immune related adverse events are autoimmune toxicities that occur in many patients treated with immune checkpoint inhibitor (ICI) cancer therapies. Our studies seek to determine the cause of these IrAEs by following immune changes over time in patients treated with ICI while monitoring for the development of IrAEs and potential biomarkers for these unwanted side effects.

    Involvement: The study involves collection of peripheral blood every 3 months for 1 year. Blood collection can be done in conjunction with Oncology visits.

    Eligibility: Adults with cancer being treated with immune checkpoint inhibitor therapy.

    Sites: UCLA and USC

    Collapse Research 
    Collapse Research Activities and Funding
    Mechanisms of Thyroid Autoimmunity in Checkpoint Immunotherapy
    NIH K08DK129829Sep 15, 2021 - Jul 30, 2026
    Role: PI
    Targets for Prevention of Autoimmune Toxicities from Checkpoint Immunotherapy
    Aramont Charitable Foundation Early Career Immunologist AwardJul 1, 2021 - Jun 30, 2024
    Role: PI
    Role of Recent Thymic T Cells in Immune Checkpoint Inhibitor Thyroiditis
    American Thyroid Association THYROIDGRANT2020-0000000169Jul 1, 2020 - Jun 30, 2022
    Role: PI

    Collapse Featured Content 
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov; 22(9):582-592. Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, Berkenstock MK, Bermas B, Braaten T, Budde LE, Chokshi S, Crees ZD, Davies M, Deng C, Gesthalter Y, Jain M, Jain P, Jallouk A, Kaffenberger BH, Khalil M, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Prosek J, Reddy S, Reid P, Ryan J, Ryder M, Salman H, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Zucker S, Lyons M, Awotiwon A, Hang L. PMID: 39536465.
      View in: PubMed   Mentions:
    2. A pathologically expanded, clonal lineage of IL-21-producing CD4+ T cells drives inflammatory neuropathy. J Clin Invest. 2024 Jun 11; 134(15). Seyedsadr M, Bang MF, McCarthy EC, Zhang S, Chen HC, Mohebbi M, Hugo W, Whitmire JK, Lechner MG, Su MA. PMID: 39087473; PMCID: PMC11290969.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    3. The Effect of Apalutamide on Thyroid Function in Prostate Cancer Patients. J Endocr Soc. 2024 May 23; 8(7):bvae105. Moffatt C, Lechner MG, Angell TE, Shen J, Drakaki A, Acosta GJ, Liang TZ, Tsai K. PMID: 38854906; PMCID: PMC11156616.
      View in: PubMed   Mentions:
    4. A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer. Clin Cancer Res. 2024 Apr 01; 30(7):1220-1222. Lechner MG, Brent GA. PMID: 38197869; PMCID: PMC10984766.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    5. Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy. Curr Cancer Rep. 2024 Feb 20; 5(1):168-180. Isaacs DJ, Kathuria-Prakash N, Hilder R, Lechner MG, Drakaki A. PMID: 39397890; PMCID: PMC11469208.
      View in: PubMed   Mentions:
    6. A pathologically expanded, clonal lineage of IL-21 producing CD4+ T cells drives Inflammatory neuropathy. bioRxiv. 2024 Jan 08. Seyedsadr M, Bang M, McCarthy E, Zhang S, Chen HC, Mohebbi M, Hugo W, Whitmire JK, Lechner MG, Su MA. PMID: 38260637; PMCID: PMC10802410.
      View in: PubMed   Mentions:
    7. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function. Thyroid. 2024 Feb; 34(2):158-166. Tsai K, Ma H, Liang TZ, Xing Y, Chung S, Dorff T, Bell D, Lechner MG. PMID: 38069567; PMCID: PMC10884548.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    8. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1242830. Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG. PMID: 38027216; PMCID: PMC10643762.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Position paper on olfactory dysfunction: 2023 Rhinology. 2023 10 01; 61(33):1-108. Whitcroft KL, Altundag A, Balungwe P, Boscolo-Rizzo P, Douglas R, Enecilla MLB, Fjaeldstad AW, Fornazieri MA, Frasnelli J, Gane S, Gudziol H, Gupta N, Haehner A, Hernandez AK, Holbrook EH, Hopkins C, Hsieh JW, Huart C, Husain S, Kamel R, Kim JK, Kobayashi M, Konstantinidis I, Landis BN, Lechner M, Macchi A, Mazal PP, Miri I, Miwa T, Mori E, Mullol J, Mueller CA, Ottaviano G, Patel ZM, Philpott C, Pinto JM, Ramakrishnan VR, Roth Y, Schlosser RJ, Stjärne P, Van Gerven L, Vodicka J, Welge-Luessen A, Wormald PJ, Hummel T. PMID: 37454287.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    10. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer. JAMA Otolaryngol Head Neck Surg. 2023 08 01; 149(8):735-742. Schumm MA, Shu ML, Hughes EG, Nikiforov YE, Nikiforova MN, Wald AI, Lechner MG, Tseng CH, Sajed DP, Wu JX, Yeh MW, Livhits MJ. PMID: 37382944; PMCID: PMC10311424.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors. Front Immunol. 2023; 14:1176994. Ding L, Sun L, Bu MT, Zhang Y, Scott LN, Prins RM, Su MA, Lechner MG, Hugo W. PMID: 37435085; PMCID: PMC10330698.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    12. Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis. AACE Clin Case Rep. 2023 Sep-Oct; 9(5):162-165. Chen DH, Lenz HJ, Lechner MG, Angell TE. PMID: 37736314; PMCID: PMC10509378.
      View in: PubMed   Mentions: 1  
    13. Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. Sci Transl Med. 2023 05 17; 15(696):eadg0675. Lechner MG, Zhou Z, Hoang AT, Huang N, Ortega J, Scott LN, Chen HC, Patel AY, Yakhshi-Tafti R, Kim K, Hugo W, Famini P, Drakaki A, Ribas A, Angell TE, Su MA. PMID: 37196065; PMCID: PMC10227862.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    14. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023 07 20; 41(21):3712-3723. El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. PMID: 37192435; PMCID: PMC10351941.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    15. Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis. J Endocr Soc. 2023 Feb 09; 7(4):bvad012. Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang JH, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto AL, Herold K, Lechner MG, Su MA, Tyrrell JB, Bluestone J, Anderson M, Masharani U. PMID: 36860908; PMCID: PMC9969737.
      View in: PubMed   Mentions: 6  
    16. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. J Immunol. 2022 08 15; 209(4):696-709. Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M, Pioso MS, Rodriguez ED, McCarthy EC, Hugo W, Angell TE, Drakaki A, Ribas A, Su MA. PMID: 35817515; PMCID: PMC9378719.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    17. Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon α. Pediatrics. 2022 04 01; 149(4). Dasgupta A, Tsay E, Federman N, Lechner MG, Su MA. PMID: 35274131; PMCID: PMC9804498.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 04; 20(4):387-405. Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. PMID: 35390769.
      View in: PubMed   Mentions: 153     Fields:    Translation:Humans
    19. Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis. Thyroid. 2022 05; 32(5):496-504. Mosaferi T, Tsai K, Sovich S, Wilhalme H, Kathuria-Prakash N, Praw SS, Drakaki A, Angell TE, Lechner MG. PMID: 35199588; PMCID: PMC9145255.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    20. Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity. Proc Natl Acad Sci U S A. 2022 01 25; 119(4). Wang Y, Guo L, Yin X, McCarthy EC, Cheng MI, Hoang AT, Chen HC, Patel AY, Allard Trout D, Xu E, Yakobian N, Hugo W, Howard JF, Sheu KM, Hoffmann A, Lechner MG, Su MA. PMID: 35058362; PMCID: PMC8795502.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    21. Sex Differences in Immunity. Annu Rev Immunol. 2022 04 26; 40:75-94. Wilkinson NM, Chen HC, Lechner MG, Su MA. PMID: 34985929; PMCID: PMC9805670.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    22. Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study. Clin Breast Cancer. 2022 06; 22(4):e558-e566. Kathuria-Prakash N, Antrim L, Hornstein N, Sun AW, Kang IM, Baclig NV, Angell TE, Lechner MG, Wald-Dickler N, In GK. PMID: 35027318; PMCID: PMC8677421.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    23. Insights into immune checkpoint inhibitor-induced thyroiditis. Nat Rev Endocrinol. 2021 11; 17(11):643-644. Lechner MG, Ryder M. PMID: 34471237.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer. Endocr Pract. 2021 Jul; 27(7):691-697. Schumm MA, Lechner MG, Shu ML, Ochoa JE, Kim J, Tseng CH, Leung AM, Yeh MW. PMID: 33642257.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    25. COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocr Pract. 2021 Feb; 27(2):90-94. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, In GK, Su MA, Lechner MG. PMID: 33551317; PMCID: PMC7831810.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    26. Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis. Oncologist. 2021 02; 26(2):e251-e260. Lechner MG, Bernardo AC, Lampe A, Praw SS, Tam SH, Angell TE. PMID: 32864832; PMCID: PMC7873343.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. Circ Heart Fail. 2019 11; 12(11):e006214. Eberly LA, Richterman A, Beckett AG, Wispelwey B, Marsh RH, Cleveland Manchanda EC, Chang CY, Glynn RJ, Brooks KC, Boxer R, Kakoza R, Goldsmith J, Loscalzo J, Morse M, Lewis EF, Abel S, Adams A, Anaya J, Andrews EH, Atkinson B, Avutu V, Bachorik A, Badri O, Bailey M, Baird K, Bakshi S, Balaban D, Barshop K, Baumrin E, Bayomy O, Beamesderfer J, Becker N, Berg DD, Berman AN, Blum SM, Boardman AP, Boden K, Bonacci RA, Brown S, Campbell K, Case S, Cetrone E, Charrow A, Chiang D, Clark D, Cohen AJ, Cooper A, Cordova T, Cuneo CN, de Feria AA, Deffenbacher K, DeFilippis EM, DeGregorio G, Deutsch AJ, Diephuis B, Divakaran S, Dorschner P, Downing N, Drescher C, D'Silva KM, Dunbar P, Duong D, Earp S, Eckhardt C, Elman SA, England R, Everett K, Fedotova N, Feingold-Link T, Ferreira M, Fisher H, Foo P, Foote M, Franco I, Gilliland T, Greb J, Greco K, Grewal S, Grin B, Growdon ME, Guercio B, Hahn CK, Hasselfeld B, Haydu EJ, Hermes Z, Hildick-Smith G, Holcomb Z, Holroyd K, Horton L, Huang G, Jablonski S, Jacobs D, Jain N, Japa S, Joseph R, Kalashnikova M, Kalwani N, Kang D, Karan A, Katz JT, Kellner D, Kidia K, Kim JH, Knowles SM, Kolbe L, Kore I, Koullias Y, Kuye I, Lang J, Lawlor M, Lechner MG, Lee K, Lee S, Lee Z, Limaye N, Lin-Beckford S, Lipsyc M, Little J, Loewenthal J, Logaraj R, Lopez DM, Loriaux D, Lu Y, Ma K, Marukian N, Matias W, Mayers JR, McConnell I, McLaughlin M, Meade C, Meador C, Mehta A, Messenger E, Michaelidis C, Mirsky J, Mitten E, Mueller A, Mullur J, Munir A, Murphy E, Nagami E, Natarajan A, Nsahlai M, Nze C, Okwara N, Olds P, Paez R, Pardo M, Patel S, Petersen A, Phelan L, Pimenta E, Pipilas D, Plovanich M, Pong D, Powers BW, Rao A, Ramirez Batlle H, Ramsis M, Reichardt A, Reiger S, Rengarajan M, Rico S, Rome BN, Rosales R, Rotenstein L, Roy A, Royston S, Rozansky H, Rudder M, Ryan CE, Salgado S, Sanchez P, Schulte J, Sekar A, Semenkovich N, Shannon E, Shaw N, Shorten AB, Shrauner W, Sinnenberg L, Smithy JW, Snyder G, Sreekrishnan A, Stabenau H, Stavrou E, Stergachis A, Stern R, Stone A, Tabrizi S, Tanyos S, Thomas C, Thun H, Torres-Lockhart K, Tran A, Treasure C, Tsai FD, Tsaur S, Tschirhart E, Tuwatananurak J, Venkateswaran RV, Vishnevetsky A, Wahl L, Wall A, Wallace F, Walsh E, Wang P, Ward HB, Warner LN, Weeks LD, Weiskopf K, Wengrod J, Williams JN, Winkler M, Wong JL, Worster D, Wright A, Wunsch C, Wynter JS, Yarbrough C, Yau WY, Yazdi D, Yeh J, Yialamas MA, Yozamp N, Zambrotta M, Zon R. PMID: 31658831; PMCID: PMC7183732.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    28. Treatment of Differentiated Thyroid Carcinomas. Surg Pathol Clin. 2019 Dec; 12(4):931-942. Lechner MG, Praw SS, Angell TE. PMID: 31672299.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    29. Bridging the Gap. N Engl J Med. 2019 Jan 31; 380(5):e6. Lee JT, Lechner MG, Vaidya A, Weinmann M. PMID: 30699317.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. Thyroid. 2018 04; 28(4):445-453. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. PMID: 29652597.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    31. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. Thyroid. 2018 04; 28(4):437-444. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. PMID: 29652599.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    32. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL. PMID: 26756227; PMCID: PMC4790214.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    33. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015 Mar; 135(3):695-705. Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, Carlson G, Lechner MG, Epstein AL. PMID: 25490535.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    34. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. PMID: 25343237.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    35. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. PMID: 25294906; PMCID: PMC4252612.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCells
    36. Adenosine A1 receptor antagonist, L-97-1, improves survival and protects the kidney in a rat model of cecal ligation and puncture induced sepsis. Eur J Pharmacol. 2014 Oct 05; 740:346-52. Wilson CN, Vance CO, Lechner MG, Matuschak GM, Lechner AJ. PMID: 25041842; PMCID: PMC4147868.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    37. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. PMID: 24955518; PMCID: PMC4148060.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    38. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013 Nov-Dec; 36(9):477-89. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. PMID: 24145359; PMCID: PMC3910494.
      View in: PubMed   Mentions: 189     Fields:    Translation:HumansAnimalsCells
    39. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol. 2013 Feb 27; 5(3):24. Russell S, Angell T, Lechner M, Liebertz D, Correa A, Sinha U, Kokot N, Epstein A. PMID: 24723971; PMCID: PMC3979926.
      View in: PubMed   Mentions: 65     Fields:    
    40. Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1. Urology. 2013 Feb; 81(2):464.e1-9. Russell SM, Lechner MG, Mokashi A, Megiel C, Jang JK, Taylor CR, Looijenga LH, French CA, Epstein AL. PMID: 23374840; PMCID: PMC4179199.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    41. Generation of tumor-targeted antibody-CpG conjugates. J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. Li Z, Jang JK, Lechner MG, Hu P, Khawli L, Scannell CA, Epstein AL. PMID: 23279945.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    42. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma. Clin Cancer Res. 2012 Sep 01; 18(17):4549-59. Lechner MG, Megiel C, Church CH, Angell TE, Russell SM, Sevell RB, Jang JK, Brody GS, Epstein AL. PMID: 22791880.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    43. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res. 2012 Sep 01; 18(17):4657-68. Murphy KA, Lechner MG, Popescu FE, Bedi J, Decker SA, Hu P, Erickson JR, O'Sullivan MG, Swier L, Salazar AM, Olin MR, Epstein AL, Ohlfest JR. PMID: 22781551; PMCID: PMC3432688.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    44. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011 Nov; 3(11):1317-40. Lechner MG, Russell SM, Bass RS, Epstein AL. PMID: 22053884; PMCID: PMC3226699.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    45. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol. 2011 Sep; 47(9):810-7. Russell SM, Lechner MG, Gong L, Megiel C, Liebertz DJ, Masood R, Correa AJ, Han J, Puri RK, Sinha UK, Epstein AL. PMID: 21719345; PMCID: PMC3164740.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    46. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011 Jun 09; 9:90. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein AL. PMID: 21658270; PMCID: PMC3128058.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCells
    47. A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Cancer Res. 2011 Apr 01; 17(7):1645-8. Lechner MG, Epstein AL. PMID: 21288925; PMCID: PMC4237605.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    48. Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer. 2011 Apr 01; 117(7):1478-89. Lechner MG, Lade S, Liebertz DJ, Prince HM, Brody GS, Webster HR, Epstein AL. PMID: 21425149; PMCID: PMC4175713.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    49. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010 Aug 15; 185(4):2273-84. Lechner MG, Liebertz DJ, Epstein AL. PMID: 20644162; PMCID: PMC2923483.
      View in: PubMed   Mentions: 308     Fields:    Translation:HumansCells
    50. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol. 2010 Feb 22; 2:5. Liebertz DJ, Lechner MG, Masood R, Sinha UK, Han J, Puri RK, Correa AJ, Epstein AL. PMID: 20175927; PMCID: PMC2841166.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    51. Gene expression in primate liver during viral hemorrhagic fever. Virol J. 2009 Feb 12; 6:20. Djavani M, Crasta OR, Zhang Y, Zapata JC, Sobral B, Lechner MG, Bryant J, Davis H, Salvato MS. PMID: 19216742; PMCID: PMC2657139.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    52. Thyroid Nodules and Cancer in the Elderly. Endotext. 2000. Lechner MG, Hershman JM. View Publication.
    Melissa's Networks
    Concepts (270)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (54)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California